Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing – BioSpace

WASHINGTON, July 7, 2020 /PRNewswire/ --A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners has published a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially lifesaving testing options available for both new cancer diagnoses and progression or recurrence of disease.

Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants). Analysis by The Consistent Testing Terminology Working Group (Working Group) indicates that language disparity is a primary obstacle to patient communication with providers about testing for their specific cancer type. Further, development of consistent language can increase patient understanding and communication, facilitate shared decision making, support value-based care, and assure concordance in policy development.

The Working Group is a consortium of 20 cancer patient advocacy groups representing solid tumor and hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostic companies and testing laboratories. Over the course of many years, multiple activities, led by numerous individual patient advocacy organizations and professional societies, have developed the groundwork for this effort. The Working Group has launched a multi-faceted dissemination and communications effort to ensure that its recommendations and supporting materials are widely available among all key stakeholders within the cancer ecosystem, including providers, patient advocacy organizations, guidelines agencies, payers, and policymakers.

In developing its recommendations, the Working Group, first convened in 2019 by LUNGevity Foundation, identified 33 terms related to biomarker, genetic, and genomic testing that were being used in patient education and clinical care within the different cancer communities. In many cases, multiple terms were used to describe the same test. Various testing modalities, the source of testing samples, and the multiplicity of gene mutations currently identifiable by testing were contributing factors in this often-confusing overlap.

In the final analysis, three umbrella descriptor terms emerged as recommendations from the Working Group's milestone exploration: "Biomarker testing"was selected as the preferred term for tests that identify characteristics, targetable findings, or other test results originating from malignant tissue and blood; "genetic testing for an inherited mutation" and "genetic testing for inherited cancer risk" were selected as consensus terms for tests used to identify germline (inherited) mutations.

"Far too many patients across all cancer types are still missing out on essential tests for biomarkers and inherited mutations indicating cancer risk," said Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics at Baylor Sammons Cancer Center and Staff Pathologist at Baylor University Medical Center. "With rates of biomarker testing and genetic testing for an inherited mutation at sub-optimal levels for numerous patient populations, patients are not benefiting from biomarker-directed care or not learning about their inherited cancer risk. Confusion around testing terms is a driving factor in this undertesting and ultimately has a detrimental impact on patient care."

Adds Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity Foundation, "When someone is diagnosed with cancer, they're swept into a whirlwind of bewildering words and complex, pressing decisions. Our Working Group's goal is to help calm that storm of confusion with clear and consistent language that facilitates communication and medical decision-making. A unified voice and message from providers, industry, and the patient advocacy community about testing is absolutely vital to optimal cancer care."

An abstract on the Working Group's recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library.

The White Paper can be viewed in its entirety atwww.CommonCancerTestingTerminology.org.

Working Groupparticipating organizations include:

Patient Advocacy: CancerCare; Cancer Support Community;The CholangiocarcinomaFoundation;Clearity Foundation; Colorectal Cancer Alliance; Fight CRC; FORCE(Facing Our Risk of Cancer Empowered); International Cancer Advocacy Network; Leukemia & Lymphoma Society; The Life Raft Group; Lymphoma Research Foundation; Living Beyond Breast Cancer; Lung Cancer Action Network (LungCan); LUNGevity Foundation; National Lung Cancer Roundtable(American Cancer Society); PanCAN; Personalized Medicine Coalition; Prostate Cancer Foundation; Ovarian Cancer Research Alliance (OCRA); Sharsheret(The Jewish Breast & Ovarian Cancer Community);and Susan G. Komen.

Professional Societies: Association of Community Cancer Centers(ACCC);Association for Molecular Pathology(AMP); and National Society of Genetic Counselors(NSGC).

Industry Partners: Abbvie; Amgen;AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eli Lilly and Company; Foundation Medicine; Genentech;GlaxoSmithKline (GSK); Novartis; Myriad Women's Health; NeoGenomics; Pfizer; Personal Genome Diagnostics (PGDx); andThermo Fisher Scientific.

About LUNGevity Foundation

LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the diseasewhile promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivorsand those who help them live better and longer lives.

Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our visiona world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

About Lung Cancer in the US

Please visit http://www.LUNGevity.orgto learn more.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pan-cancer-consortium-moves-to-clarify-and-promote-consistent-use-of-common-terms-for-biomarker-and-germline-genetic-testing-301088874.html

SOURCE LUNGevity Foundation

Original post:
Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing - BioSpace

With careful adoption, soy and wheat can help maintain seniors’ muscles, says expert – Clinical Daily News – McKnight’s Long Term Care News

News > Clinical Daily News

Plant protein can help older adults maintain muscle mass, but users must adjust for any loss of animal protein when making dietary changes, say researchers.

In a new study, plant-based proteins helped to maintain the size and quality of aging muscles, wrote investigators from Kings College London. But animal proteins were more effective at helping to form muscle. A larger dose of plant protein is therefore necessary to achieve the same muscle-building response, they concluded.

Simply transitioning from an animal-based protein diet to a plant-based diet, without adjusting total protein intake, will likely be detrimental to muscle health during aging, said Professor Oliver Witard, an expert in exercise metabolism and nutrition. A more balanced and less extreme approach to changing dietary behavior, meaning eating both animal and plant-based proteins, is best, he concluded.

Plant-based diets have numerous health benefits and are becoming more popular. In fact, 39% of Americans responded that they are actively trying to eat more plant-based foods, according to a 2017 Nielsen Homescan survey.

The research was presented this week at The Physiological Societys virtual early career conference Future Physiology 2020.

Please login or register first to view this content.

LoginRegister

Next post in Clinical Daily NewsClose

Read more here:
With careful adoption, soy and wheat can help maintain seniors' muscles, says expert - Clinical Daily News - McKnight's Long Term Care News

Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality – Financial Post

The ongoing multi-country and multi-crop initiative advances Fluences and the greater horticultural industrys understanding of the interaction between light and life

AUSTIN, Texas Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, has expanded its global photobiology research program, which encompasses studies on multiple vine crops, leafy greens and medical cannabis in the United States, Canada, Germany, Belgium and the Netherlands.

Tapping into a global network of trusted research institutions

Fluence leverages a network of leading research institutions and partners for its program, including Wageningen University & Research (WUR) for tomatoes; Proefstation voor de Groenteteelt (Proefstation) to study cucumbers; Harrow Research and Development Centre for peppers; The Technical University of Munichs Greenhouse Lab Centre for lettuce; Wageningen Plant Researchs Greenhouse Horticulture business unit and Compassionate Cultivation for medical cannabis.

The latest studies utilized Fluences VYPR Series top light and expanded PhysioSpec spectra offeringwhich features four spectra and market-leading efficacies up to 3.8 mol/Jin a randomized block design with triple replicates during a winter growing season. A leader in global horticultural research, WUR explored the impact of each spectrum on Merlice and Brioso tomato cultivars.

Traditionally, tomato plants are grown under high-pressure sodium lights, where only one spectrum is available to growers, said Ep Heuvelink, associate professor of horticulture and product physiology at WUR. Given the efficacy of Fluences LED solutions and the companys spectra options, its critical to understand how various tomato cultivars perform under LEDs and diversified spectra.

Featuring a 1.3-hectare greenhouse with 38 independent compartments, Proefstations facility brings more than 50 years of experience in research on the cultivation of greenhouse and field vegetables.

Light spectra have an important impact on plant and fruit quality, and weve found that LEDs provide a more optimal, precise spectrum than HPS, said Jonas De Win, lead cucumber researcher at Proefstation. This research is critical for our growers who frequently ask which spectra is best for their greenhouse and crop variety. Our goal is to act as the bridge between cucumber growers and the latest scientific research, enabling cultivators to enhance their environments and ultimately become more profitable.

Crop-based research results inform unique lighting strategies

LED lighting is a proven, viable option for global crop growers, said David Cohen, CEO of Fluence. Our exploration of the impact of light quality on plant development is driving a deeper conversation about efficacy, yield and quality between growers and their partners. Our commitment to leading cross-geography, multi-crop research will help guide growers in building a supplemental lighting strategy tailored to their unique business goals.

Fluence will distribute research results throughout the year, uncovering how the optimal lighting strategy varies by crop, species and environment. Results from Fluences cucumber trial with Proefstation will be previewed on July 15, 2020 on a webinar hosted by Leo Lansbergen, Fluences horticulture service specialist and expert in cucumber cultivation.

There is no one-size-fits-all approach to determining your lighting strategy, said David Hawley, Ph.D., Fluences senior scientist. Exploring how to manipulate LED technology presents a world of opportunity for us as scientists, but ultimately benefits growers looking to customize their cultivation environments. Insights derived from each study will help growers understand how various spectra impact harvests and plant quality, including factors ranging from nutrition and flavor to shelf life.

For more information about Fluence and its ongoing research initiatives, visit http://www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the worlds top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit http://www.fluence.science.

Link to high resolution pictures: http://www.fluence.science/press-links

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005470/en/

Contacts

Media Contact: For North America, Emma Chase emma@redfancommunications.com Phone: 512-917-4319

For EMEA, Silvia Nagyova s.nagyova@osram.com Phone: +49 (89) 6213-3939

#distro

Continued here:
Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality - Financial Post

Anatomage Announces Its Upcoming eBook For Students To Experience and Interact with True-Human Cadavers Online – WFMZ Allentown

SAN JOSE, Calif., July 2, 2020 /PRNewswire/ -- Anatomage Inc, a market leader in 3D medical imaging technology, today announces Anatomage eBook - an eBook that enables students to study anatomy and physiology through interacting with the anatomy of true-human cadavers online.

Anatomage eBook consists of 25 chapters that feature major anatomy and physiology concepts of 12 major body systems and functions. For each concept, users are visually guided through all of the related body parts - from macro to microstructures - with educational texts and dynamic images. As the majority of images from Anatomage eBook stem from the Anatomage Table's true-human cadavers, the digital contents exhibit accurate human anatomy content that helps students decipher and memorize anatomical terms easier.

Anatomage eBook is optimized for online learning which allows students to access the contents from anywhere. Unlike other online tools, the eBook offers a unique user experience that is highly engaging and easy to navigate. The contents are highly visual and based on Anatomage's renowned photorealistic human data.

Modeled as a dynamic web-based textbook, Anatomage eBook produces an interactive, aesthetically pleasing interface where students can explore a variety of anatomy and physiology topics using interactive controls. From tapping on the screen to scrolling the mouse, users are able to navigate through diverse anatomical parts. Adjacent and tiny structures are also highlighted with colors for distinguishment. Furthermore, cadaveric models can be rotated and engaged for a better view. Given its high interactivity, Anatomage eBook efficiently transforms the clinical and anatomical terminology into illustrative learning visuals that enhance students' memory.

Anatomage eBook is an effective learning tool for undergraduate Anatomy & Physiology students. To assist with assessing student learning, questions are included for various key topics in the textbook. Since Anatomage eBook can be accessed anywhere with Internet connectivity, it can be used as an online learning tool for both in-class and self-study sessions. By offering a multimedia platform combined with its accurate anatomy and physiology representation, Anatomage eBook embodies a new standard for digital textbooks in the medical education industry.

Adopting the Anatomage eBook will enable your students to -

For more information, please visit here or contact info@anatomage.com.

About AnatomageAs a market leader in medical virtualization technology, Anatomage enables an ecosystem of 3D anatomy hardware and software, allowing users to visualize anatomy at the highest level of accuracy. Established in both education and healthcare industries, Anatomage is transforming standard anatomy learning, medical diagnosis and treatment planning through its highly innovative products.Contact:Jack ChoiCEOAnatomage Inc.Phone: 1-408-885-1474Email: info@anatomage.comwww.anatomage.com

Read this article:
Anatomage Announces Its Upcoming eBook For Students To Experience and Interact with True-Human Cadavers Online - WFMZ Allentown

Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7…

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine

- Enhances Cue Biopharmas ability to engineer molecules for therapeutic immune modulation through Immuno-STAT and Neo-STAT platforms

CAMBRIDGE, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, today announced the peer-reviewed publication of data focused on generation and evaluation of libraries of checkpoint molecules with directed mutations providing novel biological properties in a paper titled Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.

In this work, researchers focused primarily on the recently described interaction between B7-1 and PD-L1, two molecules within the B7 superfamily, which are of critical importance for controlling anti-tumor immunity, autoimmunity and infectious diseases. By combining cell microarray and high-throughput FACS methods to screen binding events and map binding interfaces, selective mPD-L1 and mB7-1 mutants with distinct biochemical and functional properties were generated that altered the binding interactions between PD-1 and PD-L1, and CTLA-4 and B7-1 as well as the recently described PD-L1 and B7-1 binding interaction.

Our efforts expand upon the fundamental understanding of critical binding interactions and related downstream signaling cascades by more completely defining the molecular interactions between these key cell surface molecules, said Steven C. Almo, Ph.D., professor and chair of biochemistry, professor of physiology & biophysics and the Wollowick Family Foundation chair in multiple sclerosis and immunology at Albert Einstein College of Medicine, and co-founder of Cue Biopharma. Through these studies we are able to decipher specific molecular and atomic insights to engineer and generate molecules with unique biochemical and functional properties with the aim of developing more efficacious treatments with fewer unwanted side effects.

This approach augments and supplements Cue Biopharmas Immuno-STAT and Neo-STAT platforms, leveraging rational protein engineering to generate therapeutic frameworks possessing desirable drug properties while attenuating and/or abrogating unwanted, deleterious effects. CUE-101, Cue Biopharmas lead asset from the IL-2 based CUE-100 Series, was rationally engineered to enhance the selective activation of the beneficial CD8+ anti-tumor T cells, while abrogating the effects on other immune cell populations that are deleterious to cancer therapy, such as regulatory T cells. A CUE-101 Phase 1 monotherapy trial is ongoing, with enrollment of patients in dose escalation at 13 leading centers in the United States for the treatment of post first-line metastatic and recurrent HPV+ advanced head and neck cancer. Early data metrics from this trial are encouraging with demonstration of safety and tolerability, dose proportional exposure pharmacokinetics (PK) and early, albeit anecdotal, evidence of biologic activity through pharmacodynamics (PD) biomarkers and clinical benefit.

We are highly encouraged by these findings and further research being conducted in Dr. Almos laboratory, which provides us with additional, novel insights into immune receptors, said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. Learnings from this important work will augment and further advance our internal efforts to build out the Immuno-STAT and Neo-STAT platforms and enhance our ability to dial-in/dial-out specific molecular interactions for the therapeutic modulation of the immune system in cancer, autoimmune diseases and chronic infectious diseases.

Albert Einstein College of Medicine and its faculty members acknowledge the following relationships with Cue Biopharma, Inc.: Dr. Almo holds equity in Cue Biopharma, Inc., receives royalties from existing license agreements between Einstein and Cue,and is a member of its Science Advisory Board; Dr.Garrett-Thomson receives royalties; and Albert Einstein College of Medicine holds equity in Cue and receives royalties.

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered inCambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.comand follow us on Twitter https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, and our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure requiredU.S. Food and Drug Administration(FDA) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to theFDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; ; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactAshley R. RobinsonLifeSci Advisorsarr@lifesciadvisors.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com

Read the original here:
Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7...

Anatomy of the School Board Selection of Joy Klineberg – The Peoples Vanguard of Davis

The school board managed to get from 15 candidates to 1 in just three votes.

In round 1 on June 25, each board member had five votes.

Here is how they voted:

Tom Adams: Asmundson, Fulp-Cooke, Jackson, Klineberg and Taylor

Joe DiNunzio: Asmundson, Fulp-Cooke, Jackson, Klineberg and Panigrahi

Alan Fernandes: Asmundson, Jackson, Klineberg, Mauro and Taylor

Bob Poppenga: Asmundson, Darrah, Fulp-Cooke, Jackson, and Panigrahi.

That left Asmundson and Jackson with 4 votes, Klineberg and Fulp-Cooke with three, Taylor and Panigrahi with 2 going onto the next round with the other candidates as well as Darrah and Mauro not making the first cut.

Round 2 each board member had two votes.

Adams voted for Jackson and Klineberg

DiNunzio voted for Asmunson and Klineberg

Fernandes for Asmundson and Klinberg

Poppenga for Asmundson and Fulp-Cooke

That left Asmundson and Klineberg with three votes each.

Round 3 Asmundson versus Klineberg

Klineberg got three votes from Adams, DiNunzio and Fernandes

Bob Poppenga cast the lone vote for Asmundson.

It is worth noting that, at no point in time, did Bob Poppenga vote for Klineberg which meant that Klineberg was not even in Bob Poppengas top 5.

Read the original:
Anatomy of the School Board Selection of Joy Klineberg - The Peoples Vanguard of Davis

When the Facts Change, We Change Our Minds (Anatomy of a Sale) – GuruFocus.com

Even before the coronavirus, we were not big fans of the airlines business. Planes are expensive. Airlines have to pay for them whether they are fully occupied during normal economic times or when they are half-loaded during recessions. Their other big cost is fuel airlines have little control over it. If they hedge the oil price and it goes up, they are heroes. If they hedge oil and it declines, their unhedged competition will have an economic advantage. It is very difficult to develop competitive advantage; customers usually have very little loyalty and price is the deciding factor for most buying decisions.

Warren Buffett (Trades, Portfolio) invested in the airlines industry in the 80s, lost money, and swore hed never invest in it again. However, after the Great Financial Crisis the industry went through significant consolidation by mergers and attrition, leaving four carriers controlling the bulk of the market. Fewer competitors made competition more rational and turned these airlines into much better businesses. So Buffett changed his mind and bought a 10% stake in all four of the largest U.S. airlines. For a few years it seemed that he was finally right about the airlines.

Airlines were never our cup of tea. The high fixed-cost structure of the industry and its past history of going bankrupt every other recession made our EQ when it comes to airlines very low. When Buffett bought them, for some value investors, the airlines had been blessed by the high priest. We are agnostic (growing up in Soviet Russia has its rare benefits) and have to own our decisions, so we passed on the airlines without spending much time thinking about them.

Typically, when you go into recession you can look at the rear-view mirror earnings for a cyclical company and that becomes your goalpost for future earnings power within a year or two, max. We dont know how long it will take until well again see the 2019 earnings power of airlines and the travel industry in general. Here is what we know. Though it is hard to imagine this today, the fear of COVID-19 will eventually go away, either because there is a vaccine or a cure, or because the virus is gone, or because we will simply adapt to its existence.

But even in absence of a vaccine or cure, well change our behavior, and that will happen slowly on the margin. After being locked up for a few months, not seeing friends and relatives except on Zoom or Facetime, well timidly visit their houses and sit six feet apart on their porches. (My family did this on Mothers Day.) Then well invite very close friends the ones who stuck religiously to social distancing to our homes for dinner. Then we might chance visiting a restaurant with outdoor seating. Then, on a rainy day, well go inside the restaurant and find that it now has huge spacing between the tables. Well make a lot of small incremental decisions; each will be a tiny compromise that will nudge us out of our fear.

Of course, each time we read about serious virus flareups, well take one step back.

Flying is at one extreme in the spectrum of social distancing. It requires finding your way through airports packed with people and then getting on a plane that, even after the middle seats are removed will still have a higher density than a packed bar on Friday night in Manhattan. Thus flying will require a great many little, incremental, marginal decisions before we overcome the fear of boarding a plane.

Vaccine availability would instantly vanquish fear, and our behavior would come back to normal. Well, almost. There will be scar tissue on the economy trillions in government debt and persistently high unemployment that will take time to clear up. People are not flying today because we are in lockdown; theyll be flying less than they used to after lockdown is over because they are still afraid; and after their fear is gone theyll still be flying less because they cannot afford the flights.

We imagine that when Buffett bought airlines in 2015, he thought the worst case would be a significant recession where plane occupancy would fall from the usual 80-90% to 50-60% (according to the FT, only four airlines out of a few hundred are profitable at 62% occupancy). His thinking was that the airlines would lose some money for a few quarters, but the recession would be anything but an existential crisis for them. Recessions last months and expansion years, and he thought he had bought them cheap on full-cycle (both recession and expansion) earnings.

Despite being the Oracle of Omaha, he did not foresee that one day we might have a different type of recession where 95% of the planes would be grounded, not because people couldnt afford to buy a tickets but because they would be required to stay home by their governments, or would be afraid that close proximity to others would make them sick or even kill them.

Very few businesses can survive when 95% of their revenue goes away for an extended period of time. Even fewer can survive when they have a large fixed-asset base that needs to be paid for whether they are using it or not.

The sad reality is that unless airlines raise new capital, they will go bankrupt. This capital, though it might save them, will reduce the value of their businesses. Equity issuances, especially at todays depressed stock prices, would permanently dilute shareholders, as future earnings will be shared with a much-increased shareholder base.

If the airlines issue debt, it will not be cheap capital, either, and will burden these companies, which already have a lot of fixed costs, with another cost significant interest payments that will substantially reduce their future earnings power. The longer the fear of the virus lingers on, the more money these companies will lose and the greater the damage that will be done to their balance sheets and thus their future earnings power.

In our thinking about the virus we have three timelines, or eras: BC before coronavirus, DC during coronavirus (now), and AC after coronavirus (the virus is completely gone, or there is a vaccine or effective treatment. The longer the DC era lasts the more impact it has on the AC era. The DC era comes with high unemployment and enormous government spending larger deficits and an ever-growing debt pile that is no longer counted in billions but in trillions.

The future of the airlines is path-dependent, and they have little control over that path; it is controlled by the virus (or the fear of the virus).

We dont own airlines, so why am I spending so much time talking about them? There are several reasons. First, because they are companies that are antithetical to our portfolio philosophy. Charlie Munger (Trades, Portfolio) says, Tell me where I am going to die so I wont go there. So its worth having a clear picture of the types of businesses you dont want to own.

Second, we wanted to point out Buffetts ability to change his mind. Interestingly, Buffett, who was already the largest shareholder of U.S. airlines, bought more airline stocks a few weeks before he sold them. We did something similar this quarter, too: We increased our position in Melrose Industries, just to sell the full position two weeks later. (More about Melrose to follow).

Third, like Buffett, we were playing traditional chess, not realizing that the game had changed to Fischer random chess. We were following the normal recession handbook (mental models) but then realized that this is anything but a normal recession. We have to be incredibly careful about using our past mental models today; they were built in a very different environment. Today, past experience is not useless, but if relied on blindly it can be dangerous. Some things will play out in the future as they have in the past, but many wont.

We needed to start using a first-principles approach a concept we shamelessly borrowed from physics. We took out a blank piece of paper, assumed we knew nothing, and instead of continuing to think by analogy, started questioning every assumption we make in our analysis.

Our decision to sell Melrose Industries (LSE:MRO) is very similar to Buffetts sale of the airlines. We sold Melrose before the Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) annual meeting. It was a difficult decision, not because we cemented a loss but because we parted with a business we really liked, that was run by good management, and that was significantly undervalued when we bought it.

When we were buying Melrose we stress-tested it for a severe recession; however, the decline that Melrose is probably experiencing today did not occur to us in our wildest imagination. Melrose is a very strong player in two industries that have been impacted tremendously: the airlines space (it makes parts that go into planes and engines) and car parts (it is one of the largest makers of transmissions for cars). We talked to the company. It has credit lines and cash to give it immediate liquidity, but we are not sure if it will be enough.

We had applied the traditional recession mental model to our analysis, and we were wrong. Given the world we are looking at now, we should have sold it sooner.

Buying new planes is the last thing on airlines minds today. Also, only 20% of Melroses business comes from replacement parts. Melroses auto parts business (ironically, the business we worried about the most when we bought the stock) may be okay; it may even generate some profit; but we are not sure it will be able to sustain the company. We simply dont know what the losses are going to be in the airlines space and for how long. We have a tremendous respect for the Melrose management team theyre a big reason why we bought the stock but at this point the problem that Melrose is facing is bigger than them.

If you look carefully through your portfolio, youll see that weve positioned it to the opposite side of spectrum from the airlines. Most of our holdings are concentrated in four industries: defense, healthcare, tobacco (where we are permitted by clients), and telecommunications. These industries have one thing in common: They will not be structurally impacted by the virus.

Consumption of goods and services in the four industries is completely insensitive to the virus. These companies all have very stable cash flows and pricing power in the event of deflation theyll maintain their prices, while during inflation theyll raise them.

And one more thing

I am not a journalist or reporter; I am an investor who thinks through writing. This and other investment articles are just my thinking at the point they were written. However, investment research is not static, it is fluid. New information comes our way and we continue to do research, which may lead us to tweak and modify assumptions and thus to change our minds.

We are long-term investors and often hold stocks for years, but as luck may or may not have it, by the time you read this article we may have already sold the stock. I may or may not write about this company ever again. Think of this and other articles as learning and thinking frameworks. But they are not investment recommendations. The bottom line is this. If this article piques your interest in the company Ive mentioned, great. This should be the beginning, not the end, of your research.

Vitaliy Katsenelson, CFAStudent of Life

I am the CEO at IMA, which is anything but your average investment firm. (Why? Get our company brochure in your inbox here, or simply visit our website.)

In a brief moment of senility, Forbes magazine called me the new Benjamin Graham.

Ive written two books on investing, which were published by John Wiley & Sons and have been translated into eight languages. (Im working on a third - you can read a chapter from it, titled The 6 Commandments of Value Investing here.)

And if you prefer listening, audio versions of my articles are published weekly at investor.fm.

Vitaliy Katsenelson

Vitaliy N. Katsenelson, CFA, is Chief Investment Officer atInvestment Management Associatesin Denver, Colo. He is the author of The Little Book of Sideways Markets (Wiley, December 2010). To receive Vitaliys future articles by email or read his articlesclick here.Investment Management Associates Inc. is a value investing firm based in Denver, Colorado. Its main focus is on growing and preserving wealth for private investors and institutions while adhering to a disciplined value investment process, as detailed in Vitaliys bookActive Value Investing(Wiley, 2007).

Visit Vitaliy Katsenelson's Website

View post:
When the Facts Change, We Change Our Minds (Anatomy of a Sale) - GuruFocus.com

Stunningly Awful Web Overview Demos The Gruesome Anatomy of a Traditional 1-Hour Web Overview Demonstration And Some Solutions – Customer Think

In which we identify a number of common challenges with overview demos and offer solutions.

[Warning graphic and potentially painful content ahead!]

1-Hour Web Overview Demo Timeline

Heres the rough but strangely consistent timeline for most web-delivered 1 hour overview demos:

[Starting time for each element on the left side]:

00:00: Fumbling with Zoom/WebEx/GoToMeeting/Teams

Looks like John/Sue/Page/whoever is just joining now

Can you see my screen?

Looks like youre muted

Were hearing a really bad echo

(This consumption of time is delightfully known as the WebEx Tax).

00:04: Introductions, but generally one-sided

Introductions and brief personal history of each of the vendor participants, but limited information requested or offered regarding customer participants before diving in

00:06: Corporate overview presentation (gag), often including

1. Mission statement

2. Products and services (high level see next section at 00.18 for the gory details)

3. Product history and milestones

4. Founders and origins story

5. The Team

6. Revenue history and financials

7. Office locations

8. Obligatory logos slide(s) (with logos that often have nothing to do with this customers market)

9. Customer testimonials (actually the most useful part of corporate overview presentations, but often ignored by the vendor Why?)

00:18: Product overview presentation (yawn), including

1. Obligatory architecture slide(s), with equally obligatory rectangles and cylinders representing software and database components (how novel)

2. Equally obligatory product-centric slide (showing companys product in the center of a circle of other things (e.g., users, other applications, process steps, you name it so novel, once again!)

3. Key differentiators, presented without context to the customers needs or specific situation (and largely forgotten by the customer, since they havent yet seen a solution that makes remembering anything relevant)

4. Case studies, if any, that are typically skipped over because were short on time (too bad real case studies would be the most interesting section)

00:26: Actual demo, including

1. Slide that says, Demo (which lets the audience know that everything from this point forward is fake)

2. Opening statement that We planned on 45 minutes for the demo, but we only have 30 minutes remaining, so well have to go really fast

3. Followed immediately by, But wed like this be interactive, so please stop me if you have any questions (while the presenter is actually thinking, But please dont stop me because Ive got so much to cover and youll interrupt my flow!)

4. Brief introduction of the plan for a story and 5 fictional characters whose day in the life will be followed in the demo

5. Followed by a firehose-like delivery with the presenter speaking non-stop for 4, 6, or 8 minutes or longer (I just saw an overview demo where the presenter went on for 40 minutes non-stop!)

a) Interspersed with the obligatory, Any questions so far?

Customer response? Nope, were good

b) Or Does that make sense?

Customer response? Um, yes (What else could the customer say to that?)

6. Overview of navigation elements

7. Introduction and definitions of vendor jargon, acronyms and product names (e.g., What we call a _____)

8. Repeated comment that everything is configurable

9. Repeated comment that everything can drill-down to the underlying data

10. Details on how to set up the application, (even though this task is typically done only once, when first implemented, and often by the vendors implementation team)

11. A walk-through of the workflow (a run-through, in fact, since time is really getting short)

a) Exploration of as many if, or, and also options as possible

b) Frequent references to, Remember when I (that arent remembered by the audience)

c) Zippy-Mouse-Syndrome mouse movements exacerbated by a tiny mouse cursor that can barely be seen with the naked eye

d) Made even worse through the lack of use of annotation tools

e) Made yet worse by the vendor presenting from a high-resolution monitor to audience members laptops (I cant read the text)

12. The occasional piling on of a feature description by the salesperson, immediately after a perfectly adequate explanation by the presenter

13. Pre-answering questions that youve heard frequently (but werent asked)

14. Being driven into the weeds by a random question from a low-level customer team member

15. Cutting off customer questions before the customer finishes (because youve heard the question so many times before)

16. Not confirming that you actually answered the customers question, before moving on

17. A rapid verbal description of the canned and custom reporting and dashboard capabilities:

a) Often including the claim that we have over 600 canned reports/dashboards of which a typical user might only consume a few!

b) Discussion of broad report and dashboard editing and creation capabilities

c) Repeated comment that everything can drill-down to the underlying data

18. Showing data that is obviously fake and/or lacks problems to solve, opportunities to exploit, or exceptions to investigate

19. Comment that we didnt have enough time to show you everything

20. No summaries whatsoever just a firehose furiously flinging features, functions, and facts

21. No analogies or metaphors to improve memory retention for the audience

22. No stories to cement memories, either

23. And, of course, absolutely no communication of value

00:58 Salesperson summary, with marketing platitude value proposition statements (that have little or limited bearing on the customers specific situation)

00:60 Salesperson suggests scheduling a deep dive demo or offers a POC

Customer reaction of, Thanks well get back to you

Frightening, gruesome and remarkably common!

If the objective was to show the customer a demo then that objective was achieved but it is very doubtful that other tangible progress was made in the sale.

Very sad; and largely a waste of time for all involved.

Assessment Time Prepare Yourself!

Play a few recordings of your organizations overview demos and see how many of the items identified above you or your team does today. Score 1 point for each item committed above.

[If the recording shows that each item above was exhibited, then your score is (sadly) ~50 the good news is you have LOTS of room for improvement!]

Now for grading how did you do?

0-5 Points: A your demos are delightfully unusual (and you are likely a Great Demo! graduate!)

6-10 Points: B your demos could improve

11-15 Points: C your demos could really improve

16-20 Points: D your demos should seriously improve

20+ Points: F your demos qualify for membership in the Sales Prevention Team!

Sadly, most overview demos rate a C grade or worse. If you are comfortable with the results, read no further (and keep your expectations low!).

Read more:
Stunningly Awful Web Overview Demos The Gruesome Anatomy of a Traditional 1-Hour Web Overview Demonstration And Some Solutions - Customer Think

Grey’s Anatomy: 5 Times Callie Torres Was An Overrated Character (& 5 She Was Underrated) – Screen Rant

Over the last ten years, Grey's Anatomyhas seen a lot of significant departures from the show. While some of them had very dramatic and eventful exits, some were a little underwhelming and anti-climatic. One of these included Sara Ramrez, wholeft the show after a decade-long arc.

RELATED:Grey's Anatomy: 10 Facts About Callie Torres Many Fans Don't Know

Callie was one of the more memorable characters as fans saw her involved in someimportant and monumental storylines. She was a loyal and supportive friend, who would go to the ends of the earth to protect her loved ones. However, Callie wasn't perfect by any means. While some of her actions were underappreciated, there were also times where she had fans wanting to tear their hair out.

Despite Callie having all the qualities to make a great leader, she failed to step up when it mattered most. Her tenure as Chief Resident didn't last long after she failed to get the respect of her colleagues and made Bailey do most of her duties. When she proposed an unusual approach to operations, Callie needed her colleagues' reassurance to help her through.

Even when she got a seat on the hospital board, Callie wasn't as opinionated or vocal as the other members. Overall, she wasn't very good in pressured situations.

While Izzie and George's affair brought a lot of emotional pain (even for fans), the viewers shouldgive Callie more credit for the way she handled the situation. When most people find out their partners have had an affair, there tends to be a confrontation of some sort.

However, Callie handled the situation with maturity when she decided she wanted to talk things through. Even when Izzie humiliated her in the cafeteria, Callie took the moral high ground and walked away. How Callie managed to remain composed at this moment is anyone's guess...

While most fans believe Callie and Cristina had one of the most underrated friendships, now may be the time to really look at the flaws in the relationship. Despite Cristina being there for Callie in her time of need, the orthopedic surgeon never seemed to return the favor.

RELATED:Grey's Anatomy: 10 Reasons Why Cristina & Callie Aren't Real Friends

When Cristina was struggling with PTSD, Callie tried to pressure her into moving out. When Hunt humiliated Cristina in front of their friends, Callie didn't check in on her. Even when Owen and Cristina split up, Callie failed to show her support. Maybe this friendship is not as iconic as people believe them to be.

When fans rewatch the old episodes, did anyone else notice the special bond Callie and Meredith had? In Callie's final seasons, Meredith and the orthopedic surgeon grew closer as they bonded over their marital woes and children.

It first began when Callie stayed in Meredith's house after splitting with Arizona. While she was there, Callie helped Meredith with Bailey. When Derek and Meredith were struggling with long-distance, Callie took her out drinking and eased her fears. Callie even put her relationship with Penny on hold out of loyalty to Meredith. It's a shamethey never got more scenes before Callie left.

Season 12 saw Calzona fans' loyalty split down the middle as they battled for the custody of Sofia. While Callie has often be seen as one of the friendliest and most accommodating people, she was the complete opposite in this case. She was so cutthroat and ruthless especially when she allowed her lawyer to assassinate Arizona's character.

Not only did she degrade Arizona's social life but she also tried to make out her was a terrible mother. It's a bit ironic considering the case was brought about after Callie tried to move to another city for a woman she barely knew.

Fans have seen a lot of talented surgeons grace the halls of Grey-Sloan. However, only few get the recognition they deserve Callie being one. When it comes to Callie's surgical prowess, people tend to overlook her skills because she hasn't got accolades to her name. Yet, she too has been involved in some extraordinary and groundbreaking surgeries.

RELATED:Grey's Anatomy: Why Miranda & Callie Aren't Real Friends

Remember when she reconstructed Derek's hand by building cartilage from scratch? Or when she made Sunder Atluri walk again despite his polio making it near impossible. Let's also not forget how she made a man walk after experimenting with therapeutic hypothermia.

As evidenced by the partnership she had with Jo, Callie had the potential to be a good teacher if she put her mind to it. However, she was always seen to let herself down when she allowed her personal life to affect her professional judgment.

Remember when she neglected her Chief Resident duties because she was too concerned with Izzie and George? Or when she started treating Leah Murphy differently once she discovered the resident and Arizona had a fling. Let's not forget how she passed Webber's case onto an intern because she was still mad he didn't make her an attending.

When the writers first began exploring Callie's sexuality, the orthopedic surgeon was still in the midst of her journey of self-discovery. However, as the years progressed, the viewers had the pleasure of watching her turn into an LGTBQ+ icon as she became to embrace her bisexuality.

This was particularly resonant in the season 12 premiere, where Callie confronted a bigoted mother over her threats of her sending her daughter to a gay conversion camp. Considering how her parents struggled with her sexuality, it was good to see Callie become a vocal supporter and fight for those who had no one in their corner.

Over her ten years on the show, fans believed Callie was a loyal and attentive partner. However, her relationship with Penny showed she had a bit of a mean streak.

When Callie lost custody of Sofia, it appeared that the orthopedic surgeon blamed Penny. When the resident tried to console her, she shrugged her off and ended the relationship. All around the workplace,Callie treatedPenny coldly and dismissed her. It was a little unfair considering it could have been avoided if she had communicated with Arizona.

Over the course of the series, Callie and Arizona's relationship was tested as the couple faced many trials and tribulations. One of the biggest challenges they faced came in the aftermath of the plane crash, as it was revealed that Arizona had lost her leg. While many sympathized with Arizona's pain, not a lot of people recognize Callie's strength and struggles.

Although Callie wasn't on the plane, she suffered just as much as the "Grey Sloan Seven." She lost her best friend and the father of her child; she struggled with Arizona's recovery; she also had to look after Sofia while balancing her work life. Throughout it all, Callie proved how strong and compassionate she was.

NEXT:Grey's Anatomy: The 10 Best Couples, Ranked

Next Better Call Saul: 5 Reasons Lalo Is The Best Villain In The Breaking Bad Universe (& 5 Alternatives)

A writer, reader and tv fanatic, Kayleigh enjoys reading movie news and your film reviews. She has attained an Undergraduate degree in Creative Writing and is also the creator of the film and television blog 'The Critics' Corner'.

Read the original post:
Grey's Anatomy: 5 Times Callie Torres Was An Overrated Character (& 5 She Was Underrated) - Screen Rant

‘Grey’s Anatomy’ Star Camilla Luddington is a Britney Spears Lookalike in This Throwback Photo – Showbiz Cheat Sheet

Camilla Luddington of Greys Anatomy is awaiting the birth of her second child with husband Matthew Alan. Always active on social media, the British-born actress keeps her fans posted (pardon the pun!) on how shes spending quarantine with Alan and their 3-year-old daughter Hayden.

One follower of the Greys star recently came across a photo of Luddington that closely resembled a pop icon and decided to post it on Twitter.

Announcing her second pregnancy back in March via Instagram, Luddington communicates regularly with her fans on social media. While on lockdown amid the coronavirus crisis, the Greys actress described her daily routine while expecting a baby and keeping a toddler entertained.

Tired: Growing a human: Running around after another human: she postedon Instagram in April. Looking up baking recipes & never actually making anything: Wearing a bun for 72726 days:

The British star also confessed to feeling anxious during these unprecedented times and expressed her gratitude for her followers.

RELATED: Greys Anatomy Star Camilla Luddington Says She Would Love to Play This Character From Another Shondaland Drama

Keeping daily anxiety in check as best I can: Taking this s*it hour by hour: #saferathome: Luddington posted. thinking of you all and so much love to you and your families.

While Luddington posts plenty of fun pics and information, she also keeps it real when it comes to personal issues in her life. In March, the actress paid tribute to her late mother on social media, who passed away unexpectedly when Luddington was just 19 years old.

My mum died 17 years ago today,Luddington wrotein March on Instagram. I believe she visits me in my dreams whenever she is in them they are always so incredibly vivid and I always remember them in the morning. I miss her everyday but I know she is still with me.

The William & Kate star experienced many unresolved feelings about her mothers death after Haydens birth in April 2017. The past trauma began to cause anxiety for Luddington which prompted her to seek counseling.

RELATED: Greys Anatomy Star Camilla Luddington Posts Touching Mothers Day Photo With Daughter Hayden and a Tribute To Her Late Mom

When I had a child, a lot of my own trauma from losing my mom when I was younger kind of came up with me now being a parent to my own daughter, Luddington toldBustle. I started to get a lot of anxiety. I was constantly afraid that I was going to die early and leave her There was so much strength and, honestly, release in being able to go and seek out a therapist and speak about it to somebody,

With over 3 million followers on Instagram and 650K+ on Twitter, Luddington certainly has a strong fan base. One follower apparently stumbled across an old photo of the Greys star and remarked on the uncanny resemblance to a pop star.

I came across this photo & lmk how, just for a second, I thought this was Britney Spears, the fan captioned the pic of a blond Luddington. ps. I love u Camilla pls dont take it the wrong way haha.

The television doctor was clearly not offended in the slightest, confessing that she intended to replicate the Circus singer.

RELATED:Why Greys Anatomys Camilla Luddington Says Her First Scene With Ellen Pompeo Was Legitimately Terrible

I was 18 in this pic and trust me allllll I wanted was to be @britneyspears Luddington wrote in response.

Though the resemblance is striking, Luddington seems to be sticking with her brunette locks and Grey Sloan Memorial scrubs.

Read more here:
'Grey's Anatomy' Star Camilla Luddington is a Britney Spears Lookalike in This Throwback Photo - Showbiz Cheat Sheet